
News|Articles|June 1, 2003
Velcade (Bortezomib for injection) Millennium
Multiple myeloma treatment represents new class: proteasome inhibitors
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
ALK Testing Strategies and Navigating First-Line Treatment Options in Advanced NSCLC
2
How PBMs are tackling behavioral health
3
ALK-Positive NSCLC: Epidemiology, Prognosis, and the Critical Role of Biomarker Testing
4
Most commercial plans cover SC and IV oncology therapies at parity
5































